Abstracts

851 – Pharmacokinetics of a Novel Dose Ratio of DTG/FTC/TAF for African Children With HIV (UNIVERSAL1)

Background To accelerate development of pediatric antiretroviral formulations for children, the WHO-led Paediatric Antiretroviral Drug Optimization group regularly reviews priorities for drug development. High on this priority list is a dispersible fixed dose combination of dolutegravir (DTG), emtricitabine (FTC) and tenofovir alafenamide fumarate (TAF) for treatment of ART naïve and experienced children living with HIV. The optimal dose ratio for this novel DTG/FTC/TAF pediatric tablet is 5/15/1.88 mg…

879 – Impact of PrEP on HIV-1 Diversity & Drug Resistance in Newly Diagnosed Patients in Málaga, 2016-2023

Background In late 2019, pre-exposure prophylaxis (PrEP) for HIV infection was approved in Spain, potentially altering HIV-1 molecular epidemiology and reducing the number of new infections within transmission chains (TCs). We aimed to analyze the presence and characteristics of TCs in newly diagnosed HIV-1 patients before and after PrEP implementation, and to assess the prevalence…

885 – Potential Risks and Benefits of Over-the-Counter HIV PrEP: A Modeling Study

Background Over-the-counter (OTC) availability of HIV PrEP could improve use and persistence by removing the requirement of frequent clinician visits, laboratory testing, and associated costs. However, it is unknown whether the benefits of increased access would outweigh the potential risks associated with reduced monitoring. Methods Using an agent-based model of men who have sex with…

1078 – Measuring Provider Quality of Care in Tanzania Using Large Language Models

Background Comparable measures of provider quality are needed to improve HIV-related service delivery; however, many tools overlook the relational aspects of care. We investigated whether large language models (LLMs) can be used to extract valid and scalable measures of quality from standardized-patient (SP) transcripts in Tanzania. Methods We analyzed English translations of 139 audio-recorded SP…

310 – Dual IL-21/IL-15 Enhances CD8 T- and NK-Cell Function, Promoting Viral Control Post-ART Interruption

Background HIV persistence within cellular and anatomical viral reservoirs remains the primary barrier to a cure for HIV, with virus rebounding upon ART interruption (ATI) in most people with HIV. As such, developing interventions aimed at improving immune responses is a key priority for HIV cure strategies. Here, we investigated the effects of a combined heterodimeric…

1050 – Impact and Cost-Effectiveness of Geographic Prioritization for Delivery of Long-Acting PrEP

Background Long-acting injectable pre-exposure prophylaxis (PrEP), including Lenacapavir, offers an opportunity to accelerate HIV incidence declines in southern and eastern Africa. Given constrained HIV budgets, competing needs for health resources, and high product and delivery costs, prioritization strategies are needed to maximize HIV prevention impact and deliver value with limited health resources.  Methods We used…

1058 – Coverage and Discontinuation of Long-Acting Cabotegravir vs Oral PrEP in the Italian PrIDE Cohort

Background PrEP with oral tenofovir disoproxil fumarate/emtricitabine (F/TDF) may be frequently discontinued or poorly adhered to. Long-acting cabotegravir (CAB-LA) may overcome adherence challenges and enhance prevention coverage. Evidence from European real-world settings is lacking. Methods All PrEP users (PrU) enrolled in the PrIDE cohort from December 2024 (date of CAB availability) to August 15, 2025…

332 – The Plasma Cell–Free DNA Methylome Predicts Intact HIV Reservoir Decay During Antiretroviral Therapy

Background Identifying non-invasive biomarkers of HIV persistence is critical to the development and evaluation of cure strategies. Cell-free DNA (cfDNA), largely released into circulation by dying cells, has proven to be an invaluable biomarker in the oncology space. We recently demonstrated that plasma-derived cfDNA levels and epigenetic features predict HIV rebound kinetics following antiretroviral therapy…